Benzopyrimido-pyrrolo-oxazine-dione (R)-BPO-27 inhibits CFTR chloride channel gating by competition with ATP

Molecular Pharmacology

Volumn 88, Issue 4, 2015, Pages 689-696

  Kim, Yonjung ^a   Anderson, Marc O ^b   Park, Jinhong ^c   Lee, Min Goo ^a   Namkung, Wan ^c   Verkman, A S ^d  

^a Yonsei University College of Medicine   (South Korea)

^b SAN FRANCISCO STATE UNIVERSITY   (United States)

^c Yonsei University   (South Korea)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[4 OXO 2 THIOXO 3 (3 TRIFLUOROMETHYL)PHENYL] 5 THIAZOLIDINYLIDENE]METHYLBENZOIC ACID; 6 (5 BROMOFURAN 2 YL) 7,9 DIMETHYL 8,10 DIOXO 11 PHENYL 7,8,9,10 TETRAHYDRO 6H BENZO[B]PYRIMIDO[4',5':3,4]PYRROLO[1,2 D][1,4]OXAZINE 2 CARBOXYLIC ACID; ADENOSINE TRIPHOSPHATE; CHLORIDE CHANNEL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; OXAZINE DERIVATIVE; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; BENZOPYRIDOPYRIMIDINE; CFTR PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE;

ARTICLE; BINDING SITE; CHANNEL GATING; CONTROLLED STUDY; ENANTIOMER; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; STEREOISOMERISM; WHOLE CELL PATCH CLAMP; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HEK293 CELL LINE; METABOLISM; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE;

ADENOSINE TRIPHOSPHATE; BINDING SITES; BINDING, COMPETITIVE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; ION CHANNEL GATING; OXAZINES; PROTEIN STRUCTURE, SECONDARY; PYRIMIDINES;

EID: 84946564780     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.098368     Document Type: Article

References (39)

1. Amin R and Ratjen F (2014) Emerging drugs for cystic fibrosis. Expert Opin Emerg Drugs 19:143-155.
2. Caci E, Caputo A, Hinzpeter A, Arous N, Fanen P, Sonawane N, Verkman AS, Ravazzolo R, Zegarra-Moran O, and Galietta LJ (2008) Evidence for direct CFTR inhibition by CFTR(inh)-172 based on Arg347 mutagenesis. Biochem J 413:135-142.
3. Case DA, Darden TA, and Cheatham TE III, Simmerling CL, Wang J, Duke RE, Luo R, Walker RC, Zhang W, and Merz KM et al. (2012) AMBER 12, University of California, San Francisco.
4. Davidow CJ, Maser RL, Rome LA, Calvet JP, and Grantham JJ (1996) The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int 50:208-218.
5. Davis PB, Yasothan U, and Kirkpatrick P (2012) Ivacaftor. Nat Rev Drug Discov 11: 349-350.
6. Gilson MK and Zhou HX (2007) Calculation of protein-ligand binding affinities. Annu Rev Biophys Biomol Struct 36:21-42.
7. Götz AW, Williamson MJ, Xu D, Poole D, Le Grand S, and Walker RC (2012) Routine microsecond molecular dynamics simulations with AMBER on GPUs. 1. Generalized born. J Chem Theory Comput 8:1542-1555.
8. Guggino WB and Stanton BA (2006) New insights into cystic fibrosis: molecular switches that regulate CFTR. Nat Rev Mol Cell Biol 7:426-436.
9. Hawkins PC and Nicholls A (2012) Conformer generation with OMEGA: learning from the data set and the analysis of failures. J Chem Inf Model 52:2919-2936.
10. Hawkins PC, Skillman AG, Warren GL, Ellingson BA, and Stahl MT (2010) Conformer generation with OMEGA: Algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J Chem Inf Model 50:572-584.
11. Humphrey W, Dalke A, and Schulten K (1996) VMD: visual molecular dynamics. J Mol Graphics 14:27-38.
12. Kim Chiaw P, Eckford PD, and Bear CE (2011) Insights into the mechanisms underlying CFTR channel activity, the molecular basis for cystic fibrosis and strategies for therapy. Essays Biochem 50:233-248.
13. Kopeikin Z, Sohma Y, Li M, and Hwang TC (2010) On the mechanism of CFTR inhibition by a thiazolidinone derivative. J Gen Physiol 136:659-671.
14. Lee JH, Richter W, Namkung W, Kim KH, Kim E, Conti M, and Lee MG (2007) Dynamic regulation of cystic fibrosis transmembrane conductance regulator by competitive interactions of molecular adaptors. J Biol Chem 282:10414-10422.
15. Li H and Sheppard DN (2009) Therapeutic potential of cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors in polycystic kidney disease. BioDrugs 23: 203-216.
16. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, and Verkman AS (2002) Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 110: 1651-1658.
17. Rahman KS, Cui G, Harvey SC, and McCarty NA (2013) Modeling the conformational changes underlying channel opening in CFTR. PLoS One 8:e74574.
18. McGann M (2012) FRED and HYBRID docking performance on standardized datasets. J Comput Aided Mol Des 26:897-906.
19. Mense M, Vergani P, White DM, Altberg G, Nairn AC, and Gadsby DC (2006) In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer. EMBO J 25:4728-4739.
20. Mornon JP, Hoffmann B, Jonic S, Lehn P, and Callebaut I (2015) Full-open and closed CFTR channels, with lateral tunnels from the cytoplasm and an alternative position of the F508 region, as revealed by molecular dynamics. Cell Mol Life Sci 72:1377-1403.
21. Muanprasat C, Sonawane ND, Salinas D, Taddei A, Galietta LJ, and Verkman AS (2004) Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J Gen Physiol 124:125-137.
22. Namkung W, Kim KH, and Lee MG (2005) Base treatment corrects defects due to misfolding of mutant cystic fibrosis transmembrane conductance regulator. Gastroenterology 129:1979-1990.
23. Norimatsu Y, Ivetac A, Alexander C, O'Donnell N, Frye L, Sansom MS, and Dawson DC (2012) Locating a plausible binding site for an open-channel blocker, GlyH-101, in the pore of the cystic fibrosis transmembrane conductance regulator. Mol Pharmacol 82:1042-1055.
24. Onufriev A, Bashford D, and Case DA (2004) Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins 55:383-394.
25. Rastelli G, Del Rio A, Degliesposti G, and Sgobba M (2010) Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA. J Comput Chem 31:797-810.
26. Riordan JR (2005) Assembly of functional CFTR chloride channels. Annu Rev Physiol 67:701-718.
27. Sheppard DN and Welsh MJ (1999) Structure and function of the CFTR chloride channel. Physiol Rev 79(1, Suppl)S23-S45.
28. Snyder DS, Tradtrantip L, Battula S, Yao C, Phuan PW, Fettinger JC, Kurth MJ, and Verkman AS (2013) Absolute Configuration and Biological Properties of Enantiomers of Cftr Inhibitor Bpo-27. ACS Med Chem Lett 4:456-459.
29. Snyder DS, Tradtrantip L, Yao C, Kurth MJ, and Verkman AS (2011) Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease. J Med Chem 54:5468-5477.
30. Sonawane ND, Zhao D, Zegarra-Moran O, Galietta LJ, and Verkman AS (2007) Lectin conjugates as potent, nonabsorbable CFTR inhibitors for reducing intestinal fluid secretion in cholera. Gastroenterology 132:1234-1244.
31. Sonawane ND, Zhao D, Zegarra-Moran O, Galietta LJ, and Verkman AS (2008) Nanomolar CFTR inhibition by pore-occluding divalent polyethylene glycolmalonic acid hydrazides. Chem Biol 15:718-728.
32. Srinivasan J, Miller J, Kollman PA, and Case DA (1998) Continuum solvent studies of the stability of RNA hairpin loops and helices. J Biomol Struct Dyn 16:671-682.
33. Taddei A, Folli C, Zegarra-Moran O, Fanen P, Verkman AS, and Galietta LJ (2004) Altered channel gating mechanism for CFTR inhibition by a high-affinity thiazolidinone blocker. FEBS Lett 558:52-56.
34. Thiagarajah JR, Broadbent T, Hsieh E, and Verkman AS (2004) Prevention of toxininduced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology 126:511-519.
35. Thiagarajah JR, Ko EA, Tradtrantip L, Donowitz M, and Verkman AS (2014) Discovery and development of antisecretory drugs for treating diarrheal diseases. Clin Gastroenterol Hepatol 12:204-209.
36. Tradtrantip L, Sonawane ND, Namkung W, and Verkman AS (2009) Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model. J Med Chem 52:6447-6455.
37. Vergani P, Lockless SW, Nairn AC, and Gadsby DC (2005) CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature 433: 876-880.
38. Verkman AS and Galietta LJ (2009) Chloride channels as drug targets. Nat Rev Drug Discov 8:153-171.
39. Yang B, Sonawane ND, Zhao D, Somlo S, and Verkman AS (2008) Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol 19:1300-1310.